Advertisement

The role of autologous and allogeneic stem cell transplantation in the management of indolent B-cell lymphoma

John Kuruvilla

Article Figures & Data

Tables

  • Table 1

    Poor prognostic factors in patients undergoing SCT for FL

    Patient groupType of SCTKPSTBISexDisease typeTreatmentAge (y)Reference
    Nonrelapse mortalityRIC allo-SCT (vs ASCT)<90Yes39
    RIC allo-SCT (vs ASCT)REF>5053
    RelapseASCT (vs RIC allo-SCT)MaleREF/untreatedRT39
    RIC (vs ASCT)REF>5053
    Progression-free survivalRIC allo-SCT (vs ASCT)REF39
    <80REF>5053
    Overall survivalYesREF>6039
    REF >3 prior therapiesIncreasing age (continuous)44
    <80REF>5053
    • KPS, Karnofsky performance status; REF, chemotherapy-resistant disease (resistant to therapy prior to SCT); RT, radiation therapy (prior to SCT); TBI, total body irradiation (as part of SCT high-dose therapy).

  • Table 2

    Select outcomes of ASCT for relapsed or refractory FL

    SeriesReferenceArmNo. of patientsHDCT regimenPFS/EFS (%)PFS timepoint (y)HRPOS (%)OS timepoint (y)PComment
    CUP Trial16Chemotherapy24262.003464.07RCT, no rituximab
    Unpurged33CY-TBI5871
    Purged325577
    EBMT49Unpurged, no MR7035.810ND10RCT, no rituximab
    Purged, no MR72BEAM38.7ND
    Unpurged, MR6948.80.98ND
    Purged, MR6952.1ND
    EBMT67CR/PR1131BEAC BEAM or TBI-based39156015Registry, no rituximab
    No CR/PR15622644
    Barts/DFCI52CR/PR2+121CY-TBI555715No rituximab
    Nebraska36ASCT248BEAC BEAM R-BEAM, CY-TBI445635No rituximab
    GELA/ GOELAMS62Chemotherapy133393.005633< .001Multicenter, prior rituximab in 40%
    ASCT42BEAM or CY-TBI7392
    NCCN44CR/PR2+135BEAM, CBV or TBI-based573873Multicenter, prior rituximab in 100%
    EBMT53CR/PR2+726BEAM, CY-TBI, other485725Registry, prior rituximab in 53%
    CIBMTR39CR/PR2+250BEAM CBV, CY-TBI, Other415745Registry, FL1 and FL2, prior rituximab in 100%
    CIBMTR40CR/PR2+136BEAM, CBV, CY-TBI, other365595Registry, FL3,
    prior rituximab in 100%
    • BEAM, carmustine, etoposide, cytarabine, and melphalan; CBV, cyclophosphamide, carmustine, and etoposide; CR, complete response; CY, cyclophosphamide; EFS, event-free survival; HDCT, high-dose chemotherapy; MR, maintenance rituximab; ND, no differences; PR1, first partial response; PR2, second partial response; PR2+, beyond second partial response; R-BEAM, rituximab plus BEAM.

  • Table 3

    Selected outcomes of allo-SCT for relapsed or refractory FL

    SeriesReferencePreparative regimenNo. of patientsMRD (%)Prior rituximabNRM (%)NRM timepoint (y)PPFS/EFS (%)PFS timepoint (y)POS (%)OS timepoint (y)P
    IBMTR13MA176100NR30545%5515
    CIBMTR58MA12010026253673623
    RIC8010045285571
    EBMT54RIC ATG46100NR183NS553.015703NS
    RIC, alemtuzumab42100NR184468
    RIC, no TCD76100NR176774
    NCCN44Allo-SCT4863100243523613
    EBMT53RIC1498062223575675
    CIBMTR/EBMT FL1/239RIC26853100265585665
    CIBMTR/EBMT FL340RIC6159100275515545
    • ATG, antithymocyte globulin; MA, myeloablative; MRD, matched related donor; NR, not reported; NS, not significant; TCD, T-cell depletion.